Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Cancer Discov. 2018 Jun;8(6):686-695. doi: 10.1158/2159-8290.CD-17-1004. Epub 2018 Apr 2.

PMID:
29610121
2.

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI.

Oncogene. 2016 May 12;35(19):2413-27. doi: 10.1038/onc.2015.318. Epub 2015 Aug 24. Review.

PMID:
26300000
3.

Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.

Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C, Gurova KV.

Cell Rep. 2013 Jul 11;4(1):159-73. doi: 10.1016/j.celrep.2013.06.013. Epub 2013 Jul 3.

Supplemental Content

Loading ...
Support Center